Lenvatinib, In Treating Advanced Malignant Thyroid Tumours, Real Life Experience from University Malaya Medical Centre
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz343.072
Abstract: Abstract Background Differentiated thyroid cancer (DTC) is the commonest endocrine cancer in Malaysia. Chemotherapy and radiotherapy has limited role in managing radioactive iodine (RAI)-refractory DTC. With the understanding of the molecular profiling of DTC, various… read more here.
Keywords: dtc; malaya medical; refractory dtc; rai refractory ... See more keywords
Advanced RAI-refractory thyroid cancer: an update on treatment perspectives.
Sign Up to like & getrecommendations! Published in 2022 at "Endocrine-related cancer"
DOI: 10.1530/erc-22-0006
Abstract: During the last decades the knowledge on follicular cell-derived thyroid cancer (TC) molecular biology has led to the evolution of a number of novel therapies for these tumors, mainly tyrosine kinase inhibitors (TKIs). Lenvantinib, sorafenib… read more here.
Keywords: rai refractory; thyroid cancer; treatment; cancer ... See more keywords
APOBEC SBS13 Mutational Signature—A Novel Predictor of Radioactive Iodine Refractory Papillary Thyroid Carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14061584
Abstract: Simple Summary Around 15% of papillary thyroid carcinoma (PTC) patients are not cured using standard surgery followed by radioactive iodine (RAI) therapy, and instead develop refractory disease. The aim of this study was to help… read more here.
Keywords: rai refractoriness; ptc; rai refractory; mutational signature ... See more keywords